What We Know About Three-Parent In VitroFertilization
By Jessica Cussins,
RH Reality Check
| 03. 13. 2014
The Food and Drug Administration (FDA) held a public meeting in late February to consider experimental new techniques that would modify human eggs or embryos in an attempt to allow women with severely mutated mitochondrial DNA to have a child that would not inherit the disorders that can be caused by those mutations. The meeting also considered the use of similar techniques for cases of infertility.
The numerous concerns raised during the two-day meeting made it clear that there are still gaping holes in the data and countless issues to work through. But a strange thing happened: Many people from across the political and professional spectrum unexpectedly found common ground. Apparently most people can agree that anyone who hopes to wield that kind of power carries the burden of proof that their technique works, that it would be safe, and that there are no better alternatives.
As of right now, the case for these new technologies does not look very strong.
The procedures, of which there are a couple variations, have been called everything from “mitochondrial manipulation” to “three-parent IVF...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...